Distinguishing primary and secondary translocations in multiple myeloma

Ana Gabrea, Peter Leif Bergsagel, W. Michael Kuehl

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Multiple myeloma (MM) is a malignant post-germinal center tumor of somatically-mutated, isotype-switched plasma cells that accumulate in the bone marrow. It often is preceded by a stable pre-malignant tumor called monoclonal gammopathy of undetermined significance (MGUS), which can sporadically progress to MM. Five recurrent primary translocations involving the immunoglobulin heavy chain (IgH) locus on chromosome 14q32 have been identified in MGUS and MM tumors. The five partner loci include 11q13, 6p21, 4p16, 16q23, and 20q12, with corresponding dysregulation of CYCLIN D1, CYCLIN D3, FGFR3/MMSET, c-MAF, and MAFB, respectively, by strong enhancers in the IgH locus. The five recurrent translocations, which are present in 40% of MM tumors, typically are simple reciprocal translocations, mostly having breakpoints within or near IgH switch regions but sometimes within or near VDJ or JH sequences. It is thought that these translocations are caused by aberrant IgH switch recombination, and possibly by aberrant somatic hypermutation in germinal center B cells, thus providing an early and perhaps initiating event in transformation. A MYC gene is dysregulated by complex translocations and insertions as a very late event during the progression of MM tumors. Since the IgH switch recombination and somatic hypermutation mechanism are turned off in plasma cells and plasma cell tumors, the MYC rearrangements are thought to be mediated by unknown mechanisms that contribute to structural genomic instability in all kinds of tumors. These rearrangements, which often but not always juxtapose MYC near one of the strong immunoglobulin enhancers, provide a paradigm for secondary translocations. It is hypothesized that secondary translocations not involving a MYC gene can occur at any stage of tumorigenesis, including in pre-malignant MGUS tumor cells.

Original languageEnglish (US)
Pages (from-to)1225-1233
Number of pages9
JournalDNA Repair
Volume5
Issue number9-10
DOIs
StatePublished - Sep 8 2006

Fingerprint

Multiple Myeloma
Immunoglobulin Heavy Chains
Tumors
Monoclonal Gammopathy of Undetermined Significance
Neoplasms
Germinal Center
Plasma Cells
Switches
Genetic Recombination
Plasmas
Cyclin D3
Genes
Cells
Plasmacytoma
Genomic Instability
Cyclin D1
Chromosomes
Immunoglobulins
Carcinogenesis
B-Lymphocytes

Keywords

  • Enhancer
  • Immunoglobulin heavy chain
  • MGUS
  • Multiple myeloma
  • Somatic hypermutation
  • Switch recombination

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Cite this

Distinguishing primary and secondary translocations in multiple myeloma. / Gabrea, Ana; Bergsagel, Peter Leif; Michael Kuehl, W.

In: DNA Repair, Vol. 5, No. 9-10, 08.09.2006, p. 1225-1233.

Research output: Contribution to journalArticle

Gabrea, Ana ; Bergsagel, Peter Leif ; Michael Kuehl, W. / Distinguishing primary and secondary translocations in multiple myeloma. In: DNA Repair. 2006 ; Vol. 5, No. 9-10. pp. 1225-1233.
@article{15655e3fe08449e3877bb77ce41a0c73,
title = "Distinguishing primary and secondary translocations in multiple myeloma",
abstract = "Multiple myeloma (MM) is a malignant post-germinal center tumor of somatically-mutated, isotype-switched plasma cells that accumulate in the bone marrow. It often is preceded by a stable pre-malignant tumor called monoclonal gammopathy of undetermined significance (MGUS), which can sporadically progress to MM. Five recurrent primary translocations involving the immunoglobulin heavy chain (IgH) locus on chromosome 14q32 have been identified in MGUS and MM tumors. The five partner loci include 11q13, 6p21, 4p16, 16q23, and 20q12, with corresponding dysregulation of CYCLIN D1, CYCLIN D3, FGFR3/MMSET, c-MAF, and MAFB, respectively, by strong enhancers in the IgH locus. The five recurrent translocations, which are present in 40{\%} of MM tumors, typically are simple reciprocal translocations, mostly having breakpoints within or near IgH switch regions but sometimes within or near VDJ or JH sequences. It is thought that these translocations are caused by aberrant IgH switch recombination, and possibly by aberrant somatic hypermutation in germinal center B cells, thus providing an early and perhaps initiating event in transformation. A MYC gene is dysregulated by complex translocations and insertions as a very late event during the progression of MM tumors. Since the IgH switch recombination and somatic hypermutation mechanism are turned off in plasma cells and plasma cell tumors, the MYC rearrangements are thought to be mediated by unknown mechanisms that contribute to structural genomic instability in all kinds of tumors. These rearrangements, which often but not always juxtapose MYC near one of the strong immunoglobulin enhancers, provide a paradigm for secondary translocations. It is hypothesized that secondary translocations not involving a MYC gene can occur at any stage of tumorigenesis, including in pre-malignant MGUS tumor cells.",
keywords = "Enhancer, Immunoglobulin heavy chain, MGUS, Multiple myeloma, Somatic hypermutation, Switch recombination",
author = "Ana Gabrea and Bergsagel, {Peter Leif} and {Michael Kuehl}, W.",
year = "2006",
month = "9",
day = "8",
doi = "10.1016/j.dnarep.2006.05.012",
language = "English (US)",
volume = "5",
pages = "1225--1233",
journal = "DNA Repair",
issn = "1568-7864",
publisher = "Elsevier",
number = "9-10",

}

TY - JOUR

T1 - Distinguishing primary and secondary translocations in multiple myeloma

AU - Gabrea, Ana

AU - Bergsagel, Peter Leif

AU - Michael Kuehl, W.

PY - 2006/9/8

Y1 - 2006/9/8

N2 - Multiple myeloma (MM) is a malignant post-germinal center tumor of somatically-mutated, isotype-switched plasma cells that accumulate in the bone marrow. It often is preceded by a stable pre-malignant tumor called monoclonal gammopathy of undetermined significance (MGUS), which can sporadically progress to MM. Five recurrent primary translocations involving the immunoglobulin heavy chain (IgH) locus on chromosome 14q32 have been identified in MGUS and MM tumors. The five partner loci include 11q13, 6p21, 4p16, 16q23, and 20q12, with corresponding dysregulation of CYCLIN D1, CYCLIN D3, FGFR3/MMSET, c-MAF, and MAFB, respectively, by strong enhancers in the IgH locus. The five recurrent translocations, which are present in 40% of MM tumors, typically are simple reciprocal translocations, mostly having breakpoints within or near IgH switch regions but sometimes within or near VDJ or JH sequences. It is thought that these translocations are caused by aberrant IgH switch recombination, and possibly by aberrant somatic hypermutation in germinal center B cells, thus providing an early and perhaps initiating event in transformation. A MYC gene is dysregulated by complex translocations and insertions as a very late event during the progression of MM tumors. Since the IgH switch recombination and somatic hypermutation mechanism are turned off in plasma cells and plasma cell tumors, the MYC rearrangements are thought to be mediated by unknown mechanisms that contribute to structural genomic instability in all kinds of tumors. These rearrangements, which often but not always juxtapose MYC near one of the strong immunoglobulin enhancers, provide a paradigm for secondary translocations. It is hypothesized that secondary translocations not involving a MYC gene can occur at any stage of tumorigenesis, including in pre-malignant MGUS tumor cells.

AB - Multiple myeloma (MM) is a malignant post-germinal center tumor of somatically-mutated, isotype-switched plasma cells that accumulate in the bone marrow. It often is preceded by a stable pre-malignant tumor called monoclonal gammopathy of undetermined significance (MGUS), which can sporadically progress to MM. Five recurrent primary translocations involving the immunoglobulin heavy chain (IgH) locus on chromosome 14q32 have been identified in MGUS and MM tumors. The five partner loci include 11q13, 6p21, 4p16, 16q23, and 20q12, with corresponding dysregulation of CYCLIN D1, CYCLIN D3, FGFR3/MMSET, c-MAF, and MAFB, respectively, by strong enhancers in the IgH locus. The five recurrent translocations, which are present in 40% of MM tumors, typically are simple reciprocal translocations, mostly having breakpoints within or near IgH switch regions but sometimes within or near VDJ or JH sequences. It is thought that these translocations are caused by aberrant IgH switch recombination, and possibly by aberrant somatic hypermutation in germinal center B cells, thus providing an early and perhaps initiating event in transformation. A MYC gene is dysregulated by complex translocations and insertions as a very late event during the progression of MM tumors. Since the IgH switch recombination and somatic hypermutation mechanism are turned off in plasma cells and plasma cell tumors, the MYC rearrangements are thought to be mediated by unknown mechanisms that contribute to structural genomic instability in all kinds of tumors. These rearrangements, which often but not always juxtapose MYC near one of the strong immunoglobulin enhancers, provide a paradigm for secondary translocations. It is hypothesized that secondary translocations not involving a MYC gene can occur at any stage of tumorigenesis, including in pre-malignant MGUS tumor cells.

KW - Enhancer

KW - Immunoglobulin heavy chain

KW - MGUS

KW - Multiple myeloma

KW - Somatic hypermutation

KW - Switch recombination

UR - http://www.scopus.com/inward/record.url?scp=33747894571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747894571&partnerID=8YFLogxK

U2 - 10.1016/j.dnarep.2006.05.012

DO - 10.1016/j.dnarep.2006.05.012

M3 - Article

C2 - 16829212

AN - SCOPUS:33747894571

VL - 5

SP - 1225

EP - 1233

JO - DNA Repair

JF - DNA Repair

SN - 1568-7864

IS - 9-10

ER -